Abstract:Background: Clopidogrel is a prodrug, the minority of which is converted to an active metabolite by hepatic cytochrome P-450 (CYP2C19), however, most of it is metabolized to inactive substance by hepatic carboxylesterasel (CES1). Meanwhile angiotensin-converting enzyme inhibitors (ACEIs) are mostly metabolized by CES1. We aimed to assess the impact of ACEIs on platelet inhibition by clopidogrel.Methods: We genotyped variants CES1, CYP2C19*2 and *3 in 502 patients with acute coronary syndrome (ACS) receiving clopidogrel therapy, and analyzed the effects of ACEIs on responsiveness to clopidogrel by the vasodilator-stimulated phosphoprotein (VASP) phosphorylation assay and ADP-stimulated impedance whole blood platelet aggregation assay.Results: It showed that the allele frequency of CES1 c.428A was 0% in these patients. 45.22% (227/502) of these patients were carriers of CYP2C19*2 or CYP2C9*3 loss-of-function alleles. Among them, 57.71% (131/227) of the patients with CYP2C19 variants received ACEIs therapy. In a total of 502 patients, there was no difference in the VASP-PRI or the impedance whole blood platelet aggregation assay between the ACEIs group and non-ACEIs group [56.26 +/- 14.55% versus 57.76 +/- 13.56%, p = 0.241; 0 (0 - 2) Omega vs. 0 (0 - 2) Omega, p = 0.856]. In the CYP2C19 variant patients, there was no difference in the VASP-PRI or the impedance whole blood platelet aggregation assay between ACEIs group and non-ACEIs group [57.24 +/- 15.12% versus 58.07 +/- 13.90%, p = 0.667; 0 (0 - 2) Omega versus 0 (0 - 2) Omega, p = 0.536]. In the subgroups of ACS patients (unstable angina, non-ST-segment elevation myocardial infarction, ST-segment elevation myocardial infarction), there was no difference in the VASP-PRI between the ACEIs group and non-ACEIs group [55.81 +/- 15.24% versus 58.37 +/- 13.31%, p = 0.103; 55.76 +/- 15.20% versus 49.09 +/- 15.22%, p = 0.098; 58.13 +/- 11.48% versus 61.87 +/- 10.34%, p = 0.221], and there was no difference in the impedance whole blood platelet aggregation assay between ACEIs group and non-ACEIs group [0 (0 - 2) Omega versus 0 (0 - 2) Omega, p = 0.936; 0 (0 - 2) Omega versus 0 (0 - 2) Omega, p = 0.625; 0 (0 - 1.25) Omega versus 0 (0 - 1.5) Omega, p = 0.788].Conclusions: In our study, when ACEIs were used with clopidogrel, platelet response to clopidogrel was not affected. These findings suggest that the drug interaction between clopidogrel and ACEI is of little relevance in platelet function.

Ginseng Disrupts the Metabolism of Cerebrovascular Treatment Drug Clopidogrel

Mechanistic Understanding of the Effect of Dengzhan Shengmai Capsule on the Pharmacokinetics of Clopidogrel in Rats.

The inhibitory effect of intestinal bacterial metabolite of ginsenosides on CYP3A activity.

The Drug Interactions Study of Clopidogrel in vitro

Metabolic Interaction Potential Between Clopidogrel and Sulfonylurea Antidiabetic Agents: Effects on Clopidogrel Bioactivation.

Structure-activity Relationship and Substrate-Dependent Phenomena in Effects of Ginsenosides on Activities of Drug-Metabolizing P450 Enzymes.

Ginsenoside Metabolites, Rather Than Naturally Occurring Ginsenosides, Lead to Inhibition of Human Cytochrome P450 Enzymes

Gene Polymorphisms of Insulin Secretion Signaling Pathway Associated with Clopidogrel Resistance in Han Chinese Population.

Structure-inhibition relationship of ginsenosides towards UDP-glucuronosyltransferases (UGTs).

The effects of CES 1 A 2 and CYP 2 C 19 polymorphisms on responsiveness to clopidogrel and clinical outcomes among Chinese patients with acute ischemic stroke

In Vitro Investigations into the Potential Drug Interactions of Pseudoginsenoside DQ Mediated by Cytochrome P450 and Human Drug Transporters

Drug-herb Synergistic Interactions between Clopidogrel and Natural Medicine

Ginsenoside Metabolites Inhibit P-Glycoprotein in Vitro and in Situ Using Three Absorption Models

A Pharmacokinetic and Pharmacodynamic Study of Drug-Drug Interaction Between Ginsenoside Rg1, Ginsenoside Rb1 and Schizandrin after Intravenous Administration to Rats

Effects of Extract of Schisandra chinensis Baill on Clopidogrel Pharmacokinetic for Rats

Deglycosylated ginsenosides are more potent inducers of CYP1A1, CYP1A2 and CYP3A4 expression in HepG2 cells than glycosylated ginsenosides.

Effects of ginseng components on c-DNA-expressed cytochrome P450 enzyme catalytic activity

In Vitro Interaction of Clopidogrel and Its Hydrolysate with OCT1, OCT2 and OAT1.

Effect of scutellarin on the metabolism and pharmacokinetics of clopidogrel in rats.

Angiotensin-Converting Enzyme Inhibitors' Influence on Antiplatelet Therapy of Clopidogrel in ACS.

The Dynamic Effect of Non-CYP3A4-Metabolized and CYP3A4-Metabolized Statins on Clopidogrel Resistance in Patients With Cerebral Infarction